公开(公告)号：US20250041219A1

公开(公告)日：2025-02-06

申请号：US18920652

申请日：2024-10-18

Applicant: University of Tennessee Research Foundation

Inventor： Monica M. JABLONSKI ,  Mohamed Moustafa Ibrahim MOUSTAFA

IPC: A61K9/113 ,  A61K9/00 ,  A61K31/198 ,  A61K31/7056 ,  A61K47/14 ,  A61K47/32

Abstract: Microemulsions are disclosed herein that include a discontinuous internal phase comprising an aqueous solution encompassed within an internal emulsifier, a continuous oil phase encompassing the internal phase; and an external emulsifier encompassing the oil phase. Also disclosed are methods for the use of such microemulsions as drug delivery devices, and methods for treating glaucoma and reducing intraocular pressure.

公开(公告)号：US12208093B2

公开(公告)日：2025-01-28

申请号：US17669425

申请日：2022-02-11

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human

Inventor： Ravit Boger ,  Marc Ferrer ,  Juan Marugan ,  Andres Dulcey Garcia ,  Noel Terrence Southall ,  Xin Hu

IPC: A61K31/4745 ,  A61K31/522 ,  A61K31/662 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/05 ,  A61K45/06 ,  A61P31/20 ,  A61P31/22 ,  A61K9/00

Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

公开(公告)号：US20250009712A1

公开(公告)日：2025-01-09

申请号：US18896531

申请日：2024-09-25

Applicant: Curology, Inc.

Inventor： David Lortscher

IPC: A61K31/375 ,  A61K8/34 ,  A61K8/36 ,  A61K8/362 ,  A61K8/42 ,  A61K8/49 ,  A61K8/63 ,  A61K8/67 ,  A61K31/05 ,  A61K31/16 ,  A61K31/20 ,  A61K31/203 ,  A61K31/351 ,  A61K31/353 ,  A61K31/4164 ,  A61K31/455 ,  A61K31/555 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7056 ,  A61Q19/08

Abstract: Pharmaceutical compositions for treating acne, photoaging, and uneven pigmentation comprising two or three distinct pharmaceutical ingredients are described. Methods for the treatment of acne, photoaging, and uneven pigmentation using the compositions are also described.

公开(公告)号：US20240390332A1

公开(公告)日：2024-11-28

申请号：US18666922

申请日：2024-05-17

Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH

Inventor： Carla KROH ,  Silke HAAG-DIERGARTEN ,  Ingo Ulrich LANG ,  Dagmar Maria POLOTZEK ,  Tanja Margrit ZIMMERING

IPC: A61K31/4184 ,  A61K9/00 ,  A61K9/08 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K47/54 ,  A61P9/12 ,  A61P13/12

Abstract: The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more renal diseases and/or hypertension in a non-human mammal/non-human mammal patient, such as a dog or a cat.

公开(公告)号：US12110308B2

公开(公告)日：2024-10-08

申请号：US16960819

申请日：2019-01-08

Applicant: NUCORION PHARMACEUTICALS, INC.

Inventor： Lin Zhi

IPC: C07F9/6561 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7052 ,  A61K31/7056 ,  A61K31/7076 ,  A61K38/21 ,  A61K45/06 ,  A61P1/16

CPC classification number: C07F9/65616 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/212 ,  A61K45/06 ,  A61P1/16 ,  A61K31/4162 ,  A61K31/7052 ,  A61K31/7076

Abstract: Provided herein are phosphor (n) amidatacetal and phosph (on) atacetal compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular pathways in the liver. These compounds may be effective in the treatment of hepatitis or other viral infections either alone or in combination with one or more additional therapeutic agents.

公开(公告)号：US20240325423A1

公开(公告)日：2024-10-03

申请号：US18639619

申请日：2024-04-18

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： Varsha BHATT ,  Radhakrishnan Pillai ,  Arturo Angel

IPC: A61K31/7056 ,  A61K8/22 ,  A61K8/34 ,  A61K8/49 ,  A61K8/73 ,  A61K9/00 ,  A61K9/06 ,  A61K31/192 ,  A61K31/327 ,  A61K47/02 ,  A61K47/10 ,  A61K47/32 ,  A61P17/10 ,  A61Q19/00

CPC classification number: A61K31/7056 ,  A61K8/22 ,  A61K8/345 ,  A61K8/4913 ,  A61K8/731 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/192 ,  A61K31/327 ,  A61K47/02 ,  A61K47/10 ,  A61K47/32 ,  A61P17/10 ,  A61Q19/005

Abstract: The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.

公开(公告)号：US20240252525A1

公开(公告)日：2024-08-01

申请号：US18594813

申请日：2024-03-04

Applicant: Matthew Mcleay

Inventor： Matthew Mcleay

IPC: A61K31/7056 ,  A61K9/00 ,  A61K31/02 ,  A61K31/197 ,  A61K31/198 ,  A61K31/409 ,  A61K31/4196 ,  A61K31/7068 ,  A61K31/728 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61P31/14 ,  A61P35/04

CPC classification number: A61K31/7056 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/0078 ,  A61K31/02 ,  A61K31/197 ,  A61K31/198 ,  A61K31/409 ,  A61K31/4196 ,  A61K31/7068 ,  A61K31/728 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61P31/14 ,  A61P35/04 ,  A61K2300/00

Abstract: Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

公开(公告)号：US11944669B2

公开(公告)日：2024-04-02

申请号：US18163648

申请日：2023-02-02

Applicant: Theriva Biologics, Inc.

Inventor： Michael Kaleko ,  Sheila Connelly ,  Vincent John Wacher

IPC: A61K38/50 ,  A61K9/16 ,  A61K9/50 ,  A61K31/4164 ,  A61K31/424 ,  A61K31/43 ,  A61K31/7056 ,  A61K35/74 ,  A61K35/741 ,  A61K38/14 ,  A61K45/06

CPC classification number: A61K38/50 ,  A61K9/1652 ,  A61K9/5078 ,  A61K31/4164 ,  A61K31/424 ,  A61K31/43 ,  A61K31/7056 ,  A61K35/74 ,  A61K35/741 ,  A61K38/14 ,  A61K45/06 ,  A61K9/5026 ,  A61K9/5047 ,  C12Y305/02006 ,  A61K38/14 ,  A61K2300/00 ,  A61K38/50 ,  A61K2300/00 ,  A61K31/7056 ,  A61K2300/00 ,  A61K31/43 ,  A61K2300/00 ,  A61K31/424 ,  A61K2300/00

Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

公开(公告)号：US11944632B2

公开(公告)日：2024-04-02

申请号：US17520787

申请日：2021-11-08

Applicant: SAVA HEALTHCARE LTD

Inventor： Sriram Padmanabhan ,  Vinod Ramchandra Jadhav

IPC: A61K31/53 ,  A61K9/00 ,  A61K9/16 ,  A61K31/4045 ,  A61K31/4706 ,  A61K31/4965 ,  A61K31/675 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/21 ,  A61K39/395 ,  A61P31/14

CPC classification number: A61K31/53 ,  A61K9/0075 ,  A61K9/1623 ,  A61K31/4045 ,  A61K31/4706 ,  A61K31/4965 ,  A61K31/675 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/21 ,  A61K39/3955 ,  A61P31/14

Abstract: The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:




for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.

公开(公告)号：US20240075050A1

公开(公告)日：2024-03-07

申请号：US18226071

申请日：2023-07-25

Applicant: University of Connecticut

Inventor： Yulan Xiong ,  Jianzhong Yu ,  Qinfang Liu

IPC: A61K31/7056 ,  A61K45/06 ,  A61P25/28 ,  A61P29/00

CPC classification number: A61K31/7056 ,  A61K45/06 ,  A61P25/28 ,  A61P29/00

Abstract: The present invention relates to methods and compositions for treating an LRRK2-associate disorder or condition, e.g., Parkinson's Disease, methods for reducing or preventing neuronal cell death, and methods for reducing neurodegeneration and/or neuroinflammation, in a subject in need thereof, by an agent that decreases the expression of LRRK2, e.g., an agent that induces LRRK2 mRNA decay.